Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Salarius Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company dedicated to developing novel cancer treatments by targeting epigenetic mechanisms. Their lead candidate, seclidemstat, was investigated for its potential in treating various cancers, including Ewing sarcoma and other sarcomas. Founded in 2011 and headquartered in Houston, Texas, Salarius focused on advancing therapies that could address significant unmet medical needs in oncology. In December 2023, Salarius Pharmaceuticals completed a merger with VolitionRx Limited, and subsequently, the combined company operates as VolitionRx. Information presented here primarily reflects Salarius Pharmaceuticals prior to its full integration and cessation of independent operations.
Primarily focused on research and development, clinical trial management, and corporate operations for its oncology drug pipeline.
Likely utilized shared or leased laboratory and office spaces within a larger research park or incubator (e.g., JLABS @ TMC or similar), common for clinical-stage biotech companies, providing access to advanced research equipment and collaborative environments.
As a small, clinical-stage biotech, the culture was likely agile, science-driven, and highly focused, with close collaboration among a lean team of dedicated professionals. Emphasis would have been on innovation and achieving clinical milestones.
The Houston HQ's location within the Texas Medical Center provided proximity to leading research institutions, clinicians, and a rich talent pool, crucial for a biopharmaceutical company advancing novel cancer therapies.
Prior to its merger, Salarius Pharmaceuticals was primarily focused on clinical development within the United States. While its research aimed for global impact and it may have engaged international Contract Research Organizations (CROs) for specific trial activities, it did not maintain a significant independent global operational footprint with international offices. Its therapeutic aspirations were global, contingent on successful drug development.
2450 Holcombe Blvd, Suite J-702
Houston
Texas
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Salarius Pharmaceuticals' leadership includes:
Salarius Pharmaceuticals has been backed by several prominent investors over the years, including:
The period from May 2023 to May 2024 was defined by Salarius Pharmaceuticals' merger with VolitionRx, which was completed in December 2023. Consequently, the Salarius executive team largely transitioned out of their roles as the company was integrated into VolitionRx. Most executive news pertained to the merger rather than typical standalone hires or exits for Salarius in its final months of independent operation.
Discover the tools Salarius Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its merger with VolitionRx, Salarius Pharmaceuticals likely used common corporate email formats. Emails to @salariuspharma.com are no longer active as the domain redirects or is inactive. A previously common format for the small team was likely firstinitiallast@salariuspharma.com or potentially first.last@salariuspharma.com.
finitiallast@salariuspharma.com or first.last@salariuspharma.com
Format
darthur@salariuspharma.com (example, historical format, not active)
Example
0%
Success rate
GlobeNewswire • December 19, 2023
VolitionRx Limited and Salarius Pharmaceuticals announced the successful completion of their merger. The combined company operates as VolitionRx Limited, focusing on Nu.Q® blood tests. Salarius common stock ceased trading and is no longer listed on Nasdaq....more
GlobeNewswire • August 10, 2023
Salarius Pharmaceuticals announced it had entered into a definitive agreement to merge with VolitionRx Limited. The merger aimed to combine Salarius's pipeline and expertise with VolitionRx's Nu.Q® technology platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Salarius Pharmaceuticals, are just a search away.